November 9, 2017 / 1:24 PM / a month ago

BRIEF-Myovant Sciences announces positive results from phase 3 study of Relugolix

Nov 9 (Reuters) - Myovant Sciences Ltd:

* Myovant Sciences announces positive top-line results from Takeda’s phase 3 study evaluating the efficacy and safety of Relugolix for the treatment of pain associated with uterine fibroids

* Myovant Sciences Ltd - ‍Relugolix met primary endpoint​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below